2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II

被引：1

作者：

Chao, Ting-Hsing ^{[1
,2
,3
]}

Lin, Tsung-Hsien ^{[4
,5
,6
]}

Cheng, Cheng-, I ^{[7
,8
]}

Wu, Yen-Wen ^{[9
,10
,11
]}

Ueng, Kwo-Chang

Wu, Yih-Jer ^{[12
,13
,14
]}

Lin, Wei-Wen ^{[15
]}

Leu, Hsing-Ban ^{[10
,16
,17
,18
]}

Cheng, Hao-Min ^{[19
,20
,21
,22
,23
]}

Huang, Chin-Chou ^{[10
,18
,24
]}

Wu, Chih-Cheng ^{[25
,26
,27
,28
]}

Lin, Chao-Feng ^{[29
,30
]}

Chang, Wei-Ting ^{[31
,32
,33
,34
]}

Pan, Wen-Han ^{[35
,36
,37
]}

Chen, Pey-Rong ^{[38
]}

Ting, Ke-Hsin ^{[39
]}

Su, Chun-Hung ^{[2
,3
]}

Chu, Chih-Sheng ^{[40
]}

Chien, Kuo-Liong ^{[41
,42
,43
,44
]}

Yen, Hsueh-Wei ^{[4
]}

Wang, Yu-Chen ^{[45
,46
,47
]}

Su, Ta-Chen ^{[48
,49
]}

Liu, Pang-Yen ^{[50
]}

Chang, Hsien-Yuan ^{[1
]}

Chen, Po-Wei ^{[1
]}

Jimmy, Jyh-Ming ^{[51
,52
,53
]}

Lu, Ya-Wen ^{[54
]}

Lin, Po-Lin ^{[55
]}

Wang, Chao-Ping ^{[56
,57
]}

Ko, Yu-Shien ^{[58
,59
]}

Chiang, Chern-En ^{[60
,61
,62
]}

Hou, Charles Jia-Yin ^{[14
]}

Wang, Tzung-Dau ^{[63
,64
,65
,66
]}

Lin, Yen-Hung ^{[66
,67
]}

Huang, Po-Hsun ^{[16
,18
]}

Chen, Wen-Jone ^{[68
,69
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med ,Div Cardiol, Tainan 704302, Taiwan

[2] Chung Shan Med Univ Hosp, Dept Internal Med, Div Cardiol, Taichung, Taiwan

[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan

[4] Kaohsiung Med Univ, Div Cardiol, Dept Internal Med, Kaohsiung, Taiwan

[5] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan

[6] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan

[7] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan

[8] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan

[9] Far Eastern Mem Hosp, Cardiovasc Med Ctr, Div Cardiol, New Taipei City, Taiwan

[10] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan

[11] Yuan Ze Univ, Grad Inst Med, Taoyuan, Taiwan

[12] Inst Biomed Sci, MacKay Med Coll, New Taipei City, Taiwan

[13] MacKay Med Coll, Inst Biomed Sci, New Taipei City, Taiwan

[14] MacKay Mem Hosp, Cardiovasc Ctr, Dept Internal Med, Taipei, Taiwan

[15] Taichung Vet Gen Hosp, Cardiovasc Ctr, Taichung, Taiwan

[16] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Hsinchu, Taiwan

[17] Univ Ancona, HealthCare Management Ctr, Taipei, Taiwan

[18] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan

[19] Natl Yang Ming Chiao Tung Univ, Coll Med, PhD Program Interdisciplinary Med PIM, Taipei, Taiwan

[20] Taipei Vet Gen Hosp, Div Fac Dev, Taipei, Taiwan

[21] Taipei Vet Gen Hosp, Ctr Evidence based Med, Taipei, Taiwan

[22] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Coll Med, Taipei, Taiwan

[23] Natl Yang Ming Chiao Tung Univ, Inst Hlth & Welf Policy, Coll Med, Taipei, Taiwan

[24] Natl Yang Ming Chiao Tung Univ, Inst Pharmacol, Taipei, Taiwan

[25] Natl Taiwan Univ Hosp, Ctr Qual Management, Hsinchu Branch, Hsinchu, Japan

[26] Natl Taiwan Univ, Coll Med, Taipei, Japan

[27] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu, Japan

[28] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan, Japan

[29] MacKay Med Coll, Dept Med, New Taipei City, Taiwan

[30] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan

[31] Natl Sun Yat Sen Univ, Coll Med, Kaohsiung, Taiwan

[32] Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan

[33] Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan

[34] Chi Mei Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan

[35] Acad Sinica, Inst Biomed Sci, Taipei 10764, Taiwan

[36] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan

[37] Natl Taiwan Univ, Inst Biochem & Biotechnol, Taipei, Taiwan

[38] Natl Taiwan Univ Hosp, Dept Dietet, Taipei, Taiwan

[39] Changhua Christian Hosp, Div Cardiol, Dept Internal Med, Xiluo Township, Yunlin, Taiwan

[40] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan

[41] Natl Taiwan Univ, Canc Ctr, Natl Taiwan Univ Hosp, Taipei, Taiwan

[42] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[43] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[44] Natl Taiwan Univ, Populat Hlth Res Ctr, Taipei, Taiwan

[45] Asia Univ Hosp, Div Cardiol, Taichung, Taiwan

[46] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan

[47] China Med Univ & Hosp, Coll Med, Div Cardiol, Taichung, Taiwan

[48] Natl Taiwan Univ Hosp, Dept Internal Med, Cardiovasc Ctr, Taipei, Taiwan

[49] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Med, Tainan, Taiwan

[50] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Cardiol, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2024年 / 40卷 / 06期

关键词：

Atherosclerotic cardiovascular disease; Guidelines; Primary prevention; TYPE-2; DIABETES-MELLITUS; CORONARY-ARTERY-DISEASE; FATTY LIVER-DISEASE; ALL-CAUSE MORTALITY; INDIVIDUAL-PARTICIPANT DATA; BLOOD-PRESSURE; ERECTILE DYSFUNCTION; PHYSICAL-ACTIVITY; WEIGHT-LOSS; RISK-FACTORS;

D O I：

10.6515/ACS.202411_40(6).20240724B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

For the primary prevention of atherosclerotic cardiovascular disease (ASCVD), the recommended treatment target for each modifiable risk factor is as follows: reducing body weight by 5-10%; blood pressure < 130/80 mmHg LDL-C < 160 mg/dL in those with a minimal; complete and persistent abstinence from cigarette smoking; hemoglobin A1C < 7.0%; fulfilling recommended amounts of the six food groups according to the Taiwan food guide; and moderate-intensity physical activity 150 min/wk or vigorous physical activity 75 min/wk. For the primary prevention of ASCVD by pharmacological treatment in individuals with modifiable risk factors/clinical conditions, statins are the first-line therapy for reducing LDL-C levels; some specific anti-diabetic drugs proven to be effective in randomized controlled trials for the primary prevention of ASCVD are recommended in patients with type 2 diabetes mellitus; pharmacological treatment is recommended to assist in weight management for obese patients with a body mass angiotensin-converting enzyme inhibitor, a glucagon-like peptide-1 receptor agonist, a sodium-dependent glucose cotransporter-2 inhibitor, and finerenone can be used in diabetic patients with chronic kidney disease for the primary prevention of ASCVD. Of note, healthcare providers are at full discretion in clinical practice, owing to the diversity of individuals and practice, and the availability of resources and facilities.

引用

页码：669 / 715

页数：47

共 388 条

[1] Aspirin for Primary Prevention of Cardiovascular Events [J].

Abdelaziz, Hesham K. ;

Saad, Marwan ;

Pothineni, Naga Venkata K. ;

Megaly, Michael ;

Potluri, Rahul ;

Saleh, Mohammed ;

Kon, David Lai Chin ;

Roberts, David H. ;

Bhatt, Deepak L. ;

Aronow, Herbert D. ;

Abbott, J. Dawn ;

Mehta, Jawahar L. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) :2915-2929

[2] Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [J].

Agarwal, Rajiv ;

Filippatos, Gerasimos ;

Pitt, Bertram ;

Anker, Stefan D. ;

Rossing, Peter ;

Joseph, Amer ;

Kolkhof, Peter ;

Nowack, Christina ;

Gebel, Martin ;

Ruilope, Luis M. ;

Bakris, George L. .

EUROPEAN HEART JOURNAL, 2022, 43 (06) :474-+

[3] Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary [J].

Agusti, Alvar ;

Celli, Bartolome R. ;

Criner, Gerard J. ;

Halpin, David ;

Anzueto, Antonio ;

Barnes, Peter ;

Bourbeau, Jean ;

Han, MeiLan K. ;

Martinez, Fernando J. ;

de Oca, Maria Montes ;

Mortimer, Kevin ;

Papi, Alberto ;

Pavord, Ian ;

Roche, Nicolas ;

Salvi, Sundeep ;

Sin, Don D. ;

Singh, Dave ;

Stockley, Robert ;

Lopez Varela, Victorina ;

Wedzicha, Jadwiga A. ;

Vogelmeier, Claus F. .

ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (04) :232-248

[4]

Al-Abdouh Ahmad, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P434, DOI [10.1016/j.mayocpiqo.2020.04.012, 10.1016/j.mayocpiqo.2020.04.012]

[5] Kidney Stones and Cardiovascular Events: A Cohort Study [J].

Alexander, R. Todd ;

Hemmelgarn, Brenda R. ;

Wiebe, Natasha ;

Bello, Aminu ;

Samuel, Susan ;

Klarenbach, Scott W. ;

Curhan, Gary C. ;

Tonelli, Marcello .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (03) :506-512

[6] Particulate Matter and Cardiovascular Risk in Adults with Chronic Obstructive Pulmonary Disease [J].

Alexeeff, Stacey E. ;

Deosaransingh, Kamala ;

Liao, Noelle S. ;

Van den Eeden, Stephen K. ;

Schwartz, Joel ;

Sidney, Stephen .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (02) :159-167

[7] Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].

Angulo, Paul ;

Kleiner, David E. ;

Dam-Larsen, Sanne ;

Adams, Leon A. ;

Bjornsson, Einar S. ;

Charatcharoenwitthaya, Phunchai ;

Mills, Peter R. ;

Keach, Jill C. ;

Lafferty, Heather D. ;

Stahler, Alisha ;

Haflidadottir, Svanhildur ;

Bendtsen, Flemming .

GASTROENTEROLOGY, 2015, 149 (02) :389-+

[8] KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts [J].

不详 .

KIDNEY INTERNATIONAL, 2021, 99 (03) :S26-S87

[9]

[Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1

[10]

[Anonymous], 2021, FDA Authorizes Marketing of IQOS Tobacco Heating System with 'Reduced Exposure' Information

← 1 2 3 4 5 6 7 8 9 10 →